Presentation [3] This varies by disease. Within the retina there are 60-125 million rods and 3.2-6.5 million cones. No rods are present in the fovea, although the highest density of rods is found at a distance of about 20° from the fovea. The cones are mainly concentrated in the fovea and are most densely packed within the foveola. Therefore, diseases affecting rods tend to cause visual problems at night as well as peripheral visual field defects. Diseases affecting cones cause increased sensitivity to light, loss of central vision, impaired colour vision and central visual field defects.
Diagnosis [3] Diagnosis is generally made on clinical examination and subjective testing, although it needs confirmation with electro-diagnostic tests. This helps differentiate retinal disease from choroidal disease and helps ensure accuracy of diagnosis (important in view of the genetic implications).
Fundoscopy -also using red-free light -visual field tests, electrophysiological tests and multifocal electroretinograms (ERGs) and tests evaluating colour vision may all assist in the diagnosis.
Subjective retinal tests
Colour vision tests: the best known of these are the Ishihara's test plates which distinguish between red/green colour blindness. Other, more sophisticated tests can assess for yellow colour blindness, as well as help diagnose complex and subtle degrees of colour blindness. Dark adaptometry is useful in patients complaining of night blindness (nyctalopia) -which is commonly a feature of these disorders. [4] Fluorescein angiography may help differentiate retinal from choroidal disease. ERGs record the action potential produced by the retina in response to light and show typical patterns in dark (scotopic) and light (photopic) conditions. Deviations from normal waves assist diagnosis in a similar manner to an ECG. During the test, an electrode is placed on the cornea to measure the retina's electrical responses to light. Electro-oculograms (EOGs) complement ERG measurements. They measure the standing potential between the electrically positive cornea and the electrically negative back of the eye. An abnormal EOG arises as a result of problems in the RPG. New methods are being evaluated, such as high-resolution spectral-domain optic coherence tomography (SD-OCT) and fundus autofluorescence. [3] Conventional genetic testing would be expensive and time-consuming, as mutations in more than 200 genes are involved across the diverse range of dystrophies. New methods of genetic testing offer the possibility of analysing multiple genes. The methods allow much faster and more cost-effective analyses. Management [1, 3] Management is focused on diagnosis and specialised genetic counselling. Treatment options are limited and tend to be concentrated around optometric visual rehabilitation (eg, use of aids for low vision, orientation and mobility training). Work is also underway in the field of molecular and gene therapy, as the responsible genes are increasingly being identified.
Objective retinal assessment

Genetic testing
The availability and provision of the highly specialised multidisciplinary services patients need vary throughout the UK.
There is promising research in the area of gene therapy -for example, in Leber's congenital amaurosis, which is associated with dysfunction and degeneration of photoreceptors, studies have shown some positive effects of gene therapy.
Examples of hereditary retinal disorders [5] There are a variety of hereditary retinal dystrophies, some of which are very rare. The hallmark is a loss of visual acuity. These conditions are a major cause of severe sight impairment and affect patients at all ages. They vary at the genetic level, as well as at the clinical, histological and physiopathological levels. Ongoing genetic research continues to change the understanding of pathophysiology. [3] There has been some question as to whether this condition is two diseases or one. Stargardt's disease or fundus flavimaculatus is a progressive form of juvenile macular degeneration with clinical and genetic heterogeneity. Mutations in at least four genes are responsible for similar clinical characteristics and there is a lack of clear diagnostic distinction between them. Stargardt's disease and fundus flavimaculatus are discussed here as one entity.
Stargardt's disease and fundus flavimaculatus
Stargardt's disease, with or without fundus flavimaculatus, is the most common hereditary dystrophy affecting the central retina, occurring in 1 in 8,000-10,000 people. [6] Description -also known as juvenile macular dystrophy: this is one of the two most common forms of inherited macular degeneration. It accounts for 7% of all retinal dystrophies. First described by the German ophthalmologist Karl Stargardt in 1909, it is a progressive, bilateral atrophic macular dystrophy characterised by perimacular and peripheral 'dirty grey-yellow spots' (fundus flavimaculatus).
Inheritance -mainly autosomal-recessive; there is a rare autosomal-dominant variant. Presentation -childhood (aged about 6 years) to early adulthood: bilateral (usually) decreased central vision. This is often out of proportion to the clinical picture. There is also progressive colour blindness.
Prognosis -generally poor. Most patients experience rapid deterioration of vision during the first two decades of life. Once vision drops below 6/12, progression is rapid and the visual prognosis is poor. Visual rehabilitation can achieve and maintain some degree of independence. [7] A variant which has been named fundus flavimaculatus presents later and the macula may be spared. The patient may present with central visual deterioration. Deterioration in colour vision may not be noticed until later. The distribution and number of yellowish spots may change over the course of time. Prognosis tends to be better and peripheral and night vision are unaffected. [4] Description -this group of rare disorders encompasses a range of problems from pure cone dysfunction to those with varying degrees of associated (but usually less severe) rod dysfunction. Many patients start with a pure cone problem which then progressively affects the rods over time.
Progressive cone dystrophies
Inheritance -most are sporadic but autosomal-dominant, autosomal-recessive and X-linked inheritance is also known. Presentation -aged 10-30 years: slow, progressive, bilateral visual loss (night vision better than day), photophobia, poor colour vision ± nystagmus. There may also be associated visual field defects.
Prognosis -short-term, those with less rod involvement do well but, ultimately, the outlook is poor.
Alport's syndrome [4] This is a genetic disorder affecting around 1 in 5,000 children, causing glomerulonephritis, end-stage kidney disease and sensorineural hearing loss. It can affect the eyes.
Description -the condition affects collagen type IV synthesis and results in basement membrane abnormalities which manifest themselves through chronic kidney disease and sometimes with sensorineural deafness. Various eye abnormalities are often seen including lenticonus (cone-shaped lens), keratoconus, cataracts and retinal flecks in the macula and midperiphery. These rarely threaten vision.
Inheritance -X-linked dominant. Presentation -with renal problems and, although not invariably, sensorineural deafness. Prognosis -the visual prognosis is good; acuity is not normally affected. Lenticonus can be treated by replacement of the lens, as for cataracts. Mild keratoconus can be treated with hard or piggy-back contact lenses; severe cases may require a corneal transplant.
Benign familial fleck retina [13, 14] In this rare condition the fundi are massively invaded by lesions which appeared as discrete, bright white or yellow flecks situated well behind the retinal blood vessels. The macula is always spared. Fluorescein studies reveal a healthy macula and retinal and choroidal blood vessels.
Description -benign fovea-sparing irregularly shaped lesions which densely cover the retina, extending to the far periphery.
They may appear white, yellow or grey.
Inheritance -autosomal-recessive. Presentation -asymptomatic, usually discovered by chance. Prognosis -excellent, vision is not normally affected. [2, 15, 16] LCA is the severest of all retinal dystrophies. Affected individuals usually present in the first year of life with profound sight impairment, roving nystagmus, variable retinal pathology and occasionally other systemic pathology. It is now known to be caused by at least six genes. Different mutations in several of these genes have been observed to cause retinitis pigmentosa and other retinal dystrophies. It is suggested that the LCA phenotype must therefore result from mutations which have the severest consequence.
Leber's congenital amaurosis (LCA)
The estimated prevalence is 1 : 50,000-100,000 -it is an early-onset inherited cause of severe sight impairment in childhood, characterised by a severe retinal dystrophy. It typically presents in the first year of life.
Description -visual function is usually poor and often accompanied by nystagmus, sluggish or absent pupillary responses, photophobia, high hyperopia and keratoconus. Visual acuity is rarely better than 20/400. Inheritance -variants in at least six genes have been associated with LCA or early-onset retinitis pigmentosa, leading to genetically heterogeneous inheritance.
Presentation -children are severely sight impaired either from birth or within the first few years of life. A characteristic finding is 'Franceschetti's oculo-digital sign', comprising eye poking, pressing and rubbing. Constant rubbing of the eyes results in orbital fat resorption and subsequent endophthalmos (eyes sunken into sockets). The retina may initially appear normal but a pigmentary retinopathy similar to retinitis pigmentosa is frequently observed later in childhood. The ERG is characteristically non-detectable or severely subnormal.
Prognosis -treatment is supportive. Children benefit from correction of refractive error, use of aids for low vision when possible and support in educational opportunities. When possible, children should be discouraged from repeatedly poking and pressing on their eyes. In those with residual vision, assessment for amblyopia, glaucoma or cataract is needed regularly. Gene therapy may offer benefit in the future: trials of gene replacement therapy have proved successful in restoring sight to such affected dogs. [17] Congenital stationary night blindness [15, 18] This is a group of rare, non-progressive conditions of the retina in which abnormal rod function causes impaired night vision. Most familial cases are X-linked, although autosomal dominance has been described. There are associated ocular symptoms such as myopia, hyperopia, nystagmus and reduced visual acuity.
Description -the prevalence of this condition is unknown but very low. It is present from birth. Inheritance -depending on the subtype, this may be autosomal-dominant, or autosomal-recessive, or X-linked. Presentation -poor night vision as a result in a delay or an inability to achieve normal dark-adapted rod thresholds. Patients have night blindness, reduced acuity, high myopia, nystagmus and strabismus. There are two major types -the complete form and the incomplete form. The complete form always causes night blindness, while the incomplete form does not always do so. The types are distinguished by ERG.
Prognosis -there is no progression. [19] Description -this is an umbrella term used to describe various degrees of rod monochromatism or cone monochromatism.
Congenital monochromatism
It can be associated with disorders of endocrine or hypothalamic function and with sensorineural deafness.
Inheritance -depending on subtype, autosomal-recessive or X-linked. Presentation -colour blindness: if colour vision is totally absent, the world is seen in shades of grey. There may be some colour perception in incomplete rod monochromatism. Cone monochromatism is associated with better visual acuity (6/6 to 6/9) than rod monochromatism (where this is complete, visual acuity is in the region of 6/60).
Prognosis -there is no progression.
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